{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:49:23Z","timestamp":1777625363068,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HE 5825\/11-1"],"award-info":[{"award-number":["HE 5825\/11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108430037"],"award-info":[{"award-number":["202108430037"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jpet.2025.103603","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T02:14:43Z","timestamp":1746756883000},"page":"103603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antagonism of prostate \u03b11A-adrenoceptors by verapamil in human prostate smooth muscle contraction"],"prefix":"10.1016","volume":"392","author":[{"given":"Sheng","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwafemi","family":"Kale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9144-9289","authenticated-orcid":false,"given":"Philipp","family":"Weinhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-2262","authenticated-orcid":false,"given":"Alexander","family":"Tamalunas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hennenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103603_bib1","first-page":"313","article-title":"The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?","volume":"5","author":"Adler","year":"2012","journal-title":"Mol Med Rep"},{"issue":"Suppl 1","key":"10.1016\/j.jpet.2025.103603_bib2","first-page":"S157","article-title":"The concise guide to pharmacology 2021\/22: ion channels","volume":"178","author":"Alexander","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00606652","article-title":"Pharmacokinetics of verapamil in patients with hypertension","volume":"31","author":"Anderson","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00228-006-0100-8","article-title":"Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle","volume":"62","author":"Badawi","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 4","key":"10.1016\/j.jpet.2025.103603_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1464-410X.2005.05487.x","article-title":"Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system","volume":"95","author":"Barendrecht","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.jpet.2025.103603_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5730","article-title":"Drug-induced orthostatic hypotension: cluster analysis of co-prescription patterns in older people in UK primary care","volume":"33","author":"Bhanu","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpet.2025.103603_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","article-title":"Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study","volume":"68","author":"Cindolo","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12894-015-0090-x","article-title":"Patient\u2019s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?","volume":"15","author":"Cindolo","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066708","article-title":"Calcium antagonists use and its association with lower urinary tract symptoms: a cross-sectional study","volume":"8","author":"Elhebir","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jpet.2025.103603_bib10","series-title":"Verapamil","author":"Fahie","year":"2025"},{"key":"10.1016\/j.jpet.2025.103603_bib11","unstructured":"FDA (2013) CALAN\u00ae SR (verapamil hydrochloride), sustained-relase, oral capslets."},{"key":"10.1016\/j.jpet.2025.103603_bib12","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0022-5347(17)44214-5","article-title":"Effects of calcium, calcium channel blockers and Bay K 8644 on contractions induced by muscarinic receptor stimulation of isolated bladder muscle from rabbit and man","volume":"137","author":"Fovaeus","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib13","first-page":"1","article-title":"Hypertension prevalence and control among adults: United States, 2015-2016","volume":"289","author":"Fryar","year":"2017","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.jpet.2025.103603_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.amjopharm.2011.02.004","article-title":"A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity","volume":"9","author":"Gellad","year":"2011","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.jpet.2025.103603_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","article-title":"Summary paper on the 2023 European Association of Urology Guidelines on the management of non-neurogenic male lower urinary tract symptoms","volume":"84","author":"Gravas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/164_2023_678","article-title":"Adrenoceptors in the lower urinary tract","volume":"285","author":"Hennenberg","year":"2024","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.119.13289","article-title":"Alpha-blocker use and the risk of hypotension and hypotension-related clinical events in women of advanced age","volume":"74","author":"Hiremath","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jpet.2025.103603_bib18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1002\/nau.25242","article-title":"Selective inhibition of neurogenic, but not agonist-induced contractions by phospholipase A(2) inhibitors points to presynaptic phospholipase A(2) functions in contractile neurotransmission to human prostate smooth muscle","volume":"42","author":"Hu","year":"2023","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jpet.2025.103603_bib19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s43440-024-00605-5","article-title":"Effects of carvedilol on human prostate tissue contractility and stromal cell growth pointing to potential clinical implications","volume":"76","author":"Hu","year":"2024","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.jpet.2025.103603_bib20","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00210-023-02664-6","article-title":"Organ-specific off-target effects of Pim\/ZIP kinase inhibitors suggest lack of contractile Pim kinase activity in prostate, bladder, and vascular smooth muscle","volume":"397","author":"Hu","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00210-022-02218-2","article-title":"Inhibition of neurogenic contractions in renal arteries and of cholinergic contractions in coronary arteries by the presumed inhibitor of ADP-ribosylation factor 6, NAV2729","volume":"395","author":"Huang","year":"2022","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib22","first-page":"223","article-title":"Calcium channel blocker associated lower urinary tract symptoms in males: an Australian retrospective observational study","volume":"19","author":"Hughes","year":"2011","journal-title":"Qual Prim Care"},{"key":"10.1016\/j.jpet.2025.103603_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad245","article-title":"Syncope in older adults: challenges, approach and treatment","volume":"53","author":"Jansen","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.jpet.2025.103603_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2125.1981.tb01233.x","article-title":"Systemic availability of oral verapamil and effect on PR interval in man","volume":"12","author":"Johnston","year":"1981","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00005344-198205000-00025","article-title":"Verapamil competitively inhibits alpha 1-adrenergic and muscarinic but not beta-adrenergic receptors in rat myocardium","volume":"4","author":"Karliner","year":"1982","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 9","key":"10.1016\/j.jpet.2025.103603_bib26","first-page":"S3","article-title":"Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia","volume":"6","author":"Lepor","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-5347(17)40635-5","article-title":"Effects of intravesical instillation of verapamil in patients with detrusor hyperactivity","volume":"141","author":"Mattiasson","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/gerona\/gln016","article-title":"Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older","volume":"64","author":"McDonald","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jpet.2025.103603_bib29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1177\/1060028019880305","article-title":"The Fall Risk with Alpha blockers Given InitiaL dose or Elderly status (FRAGILE) study","volume":"54","author":"McDonnell","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jpet.2025.103603_bib30","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpet.2025.103603_bib31","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.0306-5251.2001.01388.x","article-title":"A 6-month large-scale study into the safety of tamsulosin","volume":"51","author":"Michel","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.119.264143","article-title":"New author guidelines for displaying data and reporting data analysis and statistical methods in experimental biology","volume":"372","author":"Michel","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103603_bib33","first-page":"627","article-title":"Polypharmacy-an upward trend with unpredictable effects","volume":"113","author":"Mo\u00dfhammer","year":"2016","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.jpet.2025.103603_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.RES.52.2.226","article-title":"Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors","volume":"52","author":"Motulsky","year":"1983","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103603_bib35","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0024-3205(88)90458-4","article-title":"Additive competitive interaction of verapamil and quinidine at alpha-adrenergic receptors of isolated cardiac guinea pig myocytes and human platelets","volume":"42","author":"M\u00fcller","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.jpet.2025.103603_bib36","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0022-2828(82)90118-3","article-title":"The interaction of calcium antagonists (slow channel blockers) with myocardial alpha adrenoceptors","volume":"14","author":"Nayler","year":"1982","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jpet.2025.103603_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3565(25)38961-5","article-title":"Binding of [3H]prazosin to porcine aortic membranes: interaction of calcium antagonists with vascular alpha-1 adrenoceptors","volume":"236","author":"Nishimura","year":"1986","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jpet.2025.103603_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.jpet.2025.103603_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3349\/ymj.2011.52.3.420","article-title":"c-Jun NH2-terminal kinase contributes to dexmedetomidine-induced contraction in isolated rat aortic smooth muscle","volume":"52","author":"Ok","year":"2011","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.jpet.2025.103603_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5694\/mja2.50244","article-title":"Polypharmacy among older Australians, 2006-2017: a population-based study","volume":"211","author":"Page","year":"2019","journal-title":"Med J Aust"},{"key":"10.1016\/j.jpet.2025.103603_bib41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-642-16499-6_7","article-title":"Anatomy and histology of the lower urinary tract","author":"Pradidarcheep","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02550542","article-title":"Effects of verapamil on bladder instability induced by partial outflow obstruction in rat","volume":"30","author":"Saito","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jpet.2025.103603_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.7257\/1053-816X.2014.34.5.223","article-title":"Urological implications of falls in the elderly: lower urinary tract symptoms and alpha-blocker medications","volume":"34","author":"Schimke","year":"2014","journal-title":"Urol Nurs"},{"key":"10.1016\/j.jpet.2025.103603_bib44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.11005\/jbm.2015.22.1.29","article-title":"Risk of hip fractures in men with alpha-blockers: a nationwide study base on claim registry","volume":"22","author":"Seo","year":"2015","journal-title":"J Bone Metab"},{"key":"10.1016\/j.jpet.2025.103603_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1540\/jsmr.36.205","article-title":"Alpha-adrenoceptor agonists produce Ca2+ oscillations in isolated rat aorta: role of protein kinase C","volume":"36","author":"Suenaga","year":"2000","journal-title":"J Smooth Muscle Res"},{"key":"10.1016\/j.jpet.2025.103603_bib46","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2147\/PPA.S484632","article-title":"Phytomedicines in pharmacotherapy of LUTS\/BPH - what do patients think?","volume":"18","author":"Tamalunas","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jpet.2025.103603_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.884057","article-title":"Inhibition of human prostate and bladder smooth muscle contraction, vasoconstriction of porcine renal and coronary arteries, and growth-related functions of prostate stromal cells by presumed small molecule galpha(q\/11) inhibitor, YM-254890","volume":"13","author":"Tamalunas","year":"2022","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103603_bib48","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/jgs.15421","article-title":"Hypotensive drugs and syncope due to orthostatic hypotension in older adults with dementia (syncope and dementia study)","volume":"66","author":"Testa","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jpet.2025.103603_bib49","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF02209079","article-title":"Effect of calcium entry blockers on blood pressure and vasoconstrictor responses to alpha-1 adrenoceptor stimulation in conscious spontaneously hypertensive rats","volume":"1","author":"Thoolen","year":"1987","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jpet.2025.103603_bib50","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jpet.2025.103603_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172985","article-title":"Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by alpha1-blockers","volume":"873","author":"Wang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jpet.2025.103603_bib52","article-title":"The risk of fall and fracture with the initiation of a prostate-selective alpha antagonist: a population based cohort study","volume":"351","author":"Welk","year":"2015","journal-title":"BMJ"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:16Z","timestamp":1777420876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0022356525398162"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103603","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antagonism of prostate \u03b11A-adrenoceptors by verapamil in human prostate smooth muscle contraction","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103603"}}